Public Company Healthcare

Lantheus Holdings

Bedford, Massachusetts, United States

Lantheus is a radiopharmaceutical company delivering diagnostic and therapeutic radiopharmaceuticals (imaging agents and related solutions) to help clinicians find, fight, and follow disease.

Focus Areas
Radiopharmaceuticals, Diagnostic imaging agents, Therapeutic radiopharmaceuticals

Tracked deals

4

4 tracked deals across 2023-2025.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

4 buyout

Lantheus Holdings Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Lantheus Holdings. 1 2023 1 2024 2 2025

Supporting Data

Recent Transactions

  • Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront
    July 22, 2025
    Buyer
    Lantheus Holdings, Inc.
    Target
    Life Molecular Imaging Ltd.
    Seller
    Life Healthcare Group Holdings Ltd
    Industry
    Healthcare Services
    Location
    United Kingdom
    Type
    Buyout

    Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).

  • Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront
    January 28, 2025
    Buyer
    Lantheus Holdings, Inc.
    Target
    Evergreen Theragnostics, Inc.
    Industry
    Healthcare Services
    Location
    New Jersey, United States
    Type
    Buyout

    Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

  • Lantheus Acquires Meilleur Technologies (NAV-4694)
    July 15, 2024
    Buyer
    Lantheus Holdings, Inc.
    Target
    Meilleur Technologies, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

  • Lantheus Holdings Acquires Cerveau Technologies
    February 6, 2023
    Buyer
    Lantheus Holdings, Inc.
    Target
    Cerveau Technologies, Inc.
    Industry
    Pharmaceuticals
    Location
    Tennessee, United States
    Type
    Buyout

    Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 2 tracked deals by Lantheus Holdings. Pharmaceuticals Buyers & Acquisitions 2 tracked deals by Lantheus Holdings. Acquisitions in New Jersey 1 tracked deal by Lantheus Holdings. Acquisitions in Tennessee 1 tracked deal by Lantheus Holdings.

Related articles

Selling a company? Get in front of buyers like Lantheus Holdings

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →